Citation
Guo, Li, et al. "Cross-reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates With Disease Severity in COVID-19 Patients: a Retrospective Study." Emerging Microbes & Infections, vol. 10, no. 1, 2021, pp. 664-676.
Guo L, Wang Y, Kang L, et al. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021;10(1):664-676.
Guo, L., Wang, Y., Kang, L., Hu, Y., Wang, L., Zhong, J., Chen, H., Ren, L., Gu, X., Wang, G., Wang, C., Dong, X., Wu, C., Han, L., Wang, Y., Fan, G., Zou, X., Li, H., Xu, J., ... Wang, J. (2021). Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerging Microbes & Infections, 10(1), 664-676. https://doi.org/10.1080/22221751.2021.1905488
Guo L, et al. Cross-reactive Antibody Against Human Coronavirus OC43 Spike Protein Correlates With Disease Severity in COVID-19 Patients: a Retrospective Study. Emerg Microbes Infect. 2021;10(1):664-676. PubMed PMID: 33734013.
TY - JOUR
T1 - Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.
AU - Guo,Li,
AU - Wang,Yeming,
AU - Kang,Liang,
AU - Hu,Yongfeng,
AU - Wang,Linghang,
AU - Zhong,Jingchuan,
AU - Chen,Hong,
AU - Ren,Lili,
AU - Gu,Xiaoying,
AU - Wang,Geng,
AU - Wang,Conghui,
AU - Dong,Xiaojing,
AU - Wu,Chao,
AU - Han,Lianlian,
AU - Wang,Ying,
AU - Fan,Guohui,
AU - Zou,Xiaohui,
AU - Li,Haibo,
AU - Xu,Jiuyang,
AU - Jin,Qi,
AU - Cao,Bin,
AU - Wang,Jianwei,
PY - 2021/3/19/pubmed
PY - 2021/4/13/medline
PY - 2021/3/18/entrez
KW - Cross-reactivity
KW - HCoV-OC43
KW - SARS-CoV-2
KW - antibody
KW - disease severity
SP - 664
EP - 676
JF - Emerging microbes & infections
JO - Emerg Microbes Infect
VL - 10
IS - 1
N2 - Seasonal human coronaviruses (HCoVs) including HCoV-229E, -OC43, -NL63, and -HKU1 widely spread in global human populations. However, the relevance of humoral response against seasonal HCoVs to COVID-19 pathogenesis is elusive. In this study, we profiled the temporal changes of IgG antibody against spike proteins (S-IgG) of SARS-CoV-2 and seasonal HCoVs in 838 plasma samples collected from 344 COVID-19 patients. We tested the antigenic cross-reactivities of S protein between SARS-CoV-2 and seasonal HCoVs and evaluated the correlations between the levels of HCoV-OC43 S-IgG and the disease severity in COVID-19 patients. We found that SARS-CoV-2 S-IgG titres mounted until days 22-28, whereas HCoV-OC43 antibody titres increased until days 15-21 and then plateaued until day 46. However, IgG titres against HCoV-NL63, -229E, and -HKU1 showed no significant increase. A two-way cross-reactivity was identified between SARS-CoV-2 and HCoV-OC43. Neutralizing antibodies against SARS-CoV-2 were not detectable in healthy controls who were positive for HCoV-OC43 S-IgG. HCoV-OC43 S-IgG titres were significantly higher in patients with severe disease than those in mild patients at days 1-21 post symptom onset (PSO). Higher levels of HCoV-OC43 S-IgG were also observed in patients requiring mechanical ventilation. At days 1-10 PSO, HCoV-OC43 S-IgG titres correlated to disease severity in the age group over 60. Our data indicate that there is a correlation between cross-reactive antibody against HCoV-OC43 spike protein and disease severity in COVID-19 patients.
SN - 2222-1751
UR - https://www.unboundmedicine.com/medline/citation/33734013/Cross_reactive_antibody_against_human_coronavirus_OC43_spike_protein_correlates_with_disease_severity_in_COVID_19_patients:_a_retrospective_study_
DB - PRIME
DP - Unbound Medicine
ER -
